HealthEquity, Inc. (NASDAQ:HQY) Stock Position Raised by Chesley Taft & Associates LLC

Chesley Taft & Associates LLC lifted its stake in shares of HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 44.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,622 shares of the company's stock after acquiring an additional 3,897 shares during the quarter. Chesley Taft & Associates LLC's holdings in HealthEquity were worth $1,115,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Pier Capital LLC bought a new stake in shares of HealthEquity during the 4th quarter worth $8,024,000. HighTower Advisors LLC lifted its holdings in shares of HealthEquity by 4.8% in the fourth quarter. HighTower Advisors LLC now owns 95,075 shares of the company's stock valued at $9,122,000 after purchasing an additional 4,370 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in shares of HealthEquity by 4.7% in the fourth quarter. Wells Fargo & Company MN now owns 124,940 shares of the company's stock valued at $11,988,000 after purchasing an additional 5,594 shares in the last quarter. Geneva Capital Management LLC lifted its holdings in shares of HealthEquity by 24.6% in the fourth quarter. Geneva Capital Management LLC now owns 1,048,903 shares of the company's stock valued at $100,642,000 after purchasing an additional 206,894 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of HealthEquity by 2.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,086,811 shares of the company's stock valued at $104,280,000 after purchasing an additional 25,004 shares in the last quarter. 99.55% of the stock is owned by institutional investors.

HealthEquity Trading Down 0.3%

HealthEquity stock opened at $112.70 on Friday. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.20 and a quick ratio of 3.20. The company has a market capitalization of $9.75 billion, a price-to-earnings ratio of 103.39, a PEG ratio of 1.60 and a beta of 0.45. HealthEquity, Inc. has a one year low of $65.01 and a one year high of $116.65. The company's fifty day moving average price is $90.99 and its two-hundred day moving average price is $97.74.

HealthEquity (NASDAQ:HQY - Get Free Report) last posted its earnings results on Tuesday, June 3rd. The company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.81 by $0.16. The firm had revenue of $330.80 million for the quarter, compared to the consensus estimate of $322.25 million. HealthEquity had a net margin of 8.41% and a return on equity of 9.70%. During the same period in the prior year, the business posted $0.80 earnings per share. On average, analysts forecast that HealthEquity, Inc. will post 2.32 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently issued reports on HQY. Wells Fargo & Company increased their target price on HealthEquity from $110.00 to $125.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. The Goldman Sachs Group increased their target price on HealthEquity from $94.00 to $104.00 and gave the company a "neutral" rating in a report on Wednesday. Barrington Research increased their target price on HealthEquity from $112.00 to $125.00 and gave the company an "outperform" rating in a report on Thursday. Deutsche Bank Aktiengesellschaft increased their price objective on HealthEquity from $98.00 to $115.00 and gave the stock a "buy" rating in a report on Thursday. Finally, Bank of America increased their price objective on HealthEquity from $110.00 to $125.00 and gave the stock a "buy" rating in a report on Wednesday. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, HealthEquity currently has an average rating of "Buy" and an average target price of $118.09.

Insider Activity

In related news, Director Robert W. Selander sold 5,750 shares of HealthEquity stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $77.65, for a total transaction of $446,487.50. Following the sale, the director now directly owns 84,969 shares of the company's stock, valued at $6,597,842.85. This trade represents a 6.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael Henry Fiore sold 8,881 shares of HealthEquity stock in a transaction dated Friday, April 4th. The stock was sold at an average price of $78.26, for a total value of $695,027.06. Following the sale, the executive vice president now directly owns 56,655 shares in the company, valued at approximately $4,433,820.30. This trade represents a 13.55% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by company insiders.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

Want to see what other hedge funds are holding HQY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HealthEquity, Inc. (NASDAQ:HQY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.